Monitoring heart rhythms in patients starting BTK inhibitors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study enrolls patients who are beginning treatment with Bruton Tyrosine Kinase (BTK) inhibitors and have no prior history of arrhythmia. Participants will have a Medtronic LINQ-2 insertable cardiac monitor (ILR) implanted to continuously monitor for new onset atrial fibrillation and other arrhythmias. The study aims to collect data on the incidence of these arrhythmias and the responses to detected episodes over a period of up to 60 months. The approach is prospective and non-blinded, focusing on a single arm of patients receiving BTK therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \>18yo
* Willing to sign and date consent form,
* Willing to be remotely monitored
* Initiating BTK inhibitor for approved condition (i.e. CLL, Waldenstrom's, etc)
* Willing to have Medtronic cardiac monitor inserted to allow at minimum 24 hours continuous monitoring prior to initiating BTK inhibitor

Exclusion Criteria:

* Documented AF/VA in past 12 months
* Cerebral Vascular Accident (CVA) or Transient Ischemic Attack (TIA) in past year
* Has current implanted pulse generator, defibrillator, pacemaker, or resynchronization device
* heart surgery within past 90 days
* Myocardial Infarction within past 90 days
* Patient is taking an anti-arrhythmic or anticoagulant
* has concomitant condition that precludes safe participation in study (substance abuse, etc)
* Enrollment in separate study that could confound results of this study

Where it's running

• Northwell (Northshore University/Long Island Jewish Hospitals)
  New Hyde Park, New York, United States Recruiting

Study contacts

• Principal investigator: Robert S Copeland-Halperin, MD — Northwell Health
• Study coordinator: Efstathia Mihelis
• Email: emihelis@northwell.edu
• Phone: 212-434-6614

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tafasitamab plus Acalabrutinib and Venetoclax for newly treated CLL/SLL

  This phase II study tests a combination of tafasitamab, acalabrutinib, and venetoclax in adults who are newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma to see if it is safe and effective.

  Recruiting at 2 sites Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07582159

• LP-168 plus obinutuzumab for previously treated and BTK T474I‑mutated CLL/SLL

  This trial tests whether adding LP-168 to obinutuzumab helps people with previously treated CLL/SLL, including those with the BTK T474I gatekeeper mutation, achieve deeper remissions.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT06978088

• AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals

  This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.

  Recruiting at 2 sites Hospital Universitari Vall d'Hebron Research Institute · Leuven and 6 other locations · NCT07924371

• Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities

  This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.

  Recruiting University Hospital Augsburg · Augsburg, Bavaria · NCT07857044

• Dual Energy ablation with SmartTouch SF catheter in persistent atrial fibrillation

  This study tests a pulsed field and radiofrequency ablation system to treat persistent atrial fibrillation in adults who have not responded well to prior medications.

  Recruiting at 4 sites Biosense Webster, Inc. · Beijing and 3 other locations · NCT07845682

• Predicting high-risk arrhythmic events in people with arrhythmic mitral valve prolapse

  This study tests a risk model to see which patients with arrhythmic mitral valve prolapse might need an ICD.

  Recruiting Oslo University Hospital · Oslo · NCT07830888

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.